ProQR logo1200x1200.png
ProQR to Present at Upcoming Scientific Conferences
November 18, 2019 07:23 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR logo1200x1200.png
ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
October 15, 2019 16:08 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR logo1200x1200.png
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
October 10, 2019 06:00 ET | ProQR Therapeutics N.V.
Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated...
ProQR logo1200x1200.png
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
October 07, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR logo1200x1200.png
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
September 09, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
34945.jpg
ProQR to Present at the JMP Securities Life Sciences Conference
June 03, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands and CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
34945.jpg
ProQR to Present at the H.C. Wainwright Global Life Sciences Conference
April 01, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
34945.jpg
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
March 11, 2019 08:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
34945.jpg
ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
January 07, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
34945.jpg
ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
January 02, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...